Cleerly ISCHEMIA
Detection of Vessel-Specific Coronary Ischemia
FDA-ClearedCommercial
Key Facts
Indication
Detection of Vessel-Specific Coronary Ischemia
Phase
FDA-Cleared
Status
Commercial
Company
About Cleerly
Cleerly's mission is to eliminate heart attacks by creating a new global standard of precision heart care. The company leverages artificial intelligence trained on millions of images from over 40,000 patients to provide physicians with detailed, quantitative, and actionable insights into coronary artery disease from standard CCTA scans. Its platform is supported by a robust body of clinical evidence from major trials like CREDENCE and PACIFIC, demonstrating high diagnostic accuracy for ischemia and prognostic value for major adverse cardiac events (MACE). Cleerly is focused on driving adoption among healthcare providers, payors, and patients to transform cardiac risk assessment.
View full company profile